Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

RNA Splicing01:32

RNA Splicing

56.9K
Splicing is the process by which eukaryotic RNA is edited before its translation into protein. The RNA strand transcribed from eukaryotic DNA is called the primary transcript. The primary transcripts that become mRNAs are called precursor messenger RNAs (pre-mRNAs). Eukaryotic pre-mRNA contains alternating sequences of exons and introns. Exons are nucleotide sequences that code for proteins, whereas introns are the non-coding regions. In RNA splicing, introns are removed and exons are bonded...
56.9K
Alternative RNA Splicing02:18

Alternative RNA Splicing

21.7K
Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
21.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Mesoporous Framework-Shell Integration on Visible Semiconducting Polymer Nanoparticles for Photo-Driven Antibacterial Therapy.

Advanced healthcare materials·2026
Same author

Bilateral thoracic paravertebral block for robotic hepatectomy without hepatic portal occlusion for a cirrhosis patient: a case report.

Frontiers in oncology·2026
Same author

Zinc-Coordinated Trienzyme Nanogel Cascade Therapy for Accelerated Post-Pancreatectomy Cutaneous Wound Healing.

Advanced materials (Deerfield Beach, Fla.)·2025
Same author

SenExo-cCCT2 Reprograms Senescence Response and Anti-Tumor Immunity Following FOLFIRINOX Chemotherapy in Pancreatic Ductal Adenocarcinoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2025
Same author

Laparoscopic versus open secondary hepatectomy treating postoperative regional recurrent hepatolithiasis: a multicenter real-world study.

Surgical endoscopy·2025
Same journal

Perioperative tislelizumab for early-stage hepatocellular carcinoma: A phase II trial with integrated tumour microenvironment profiling and predictive modeling.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same journal

Tailored HER2 ECD mRNA-LNP vaccines boost CD8<sup>+</sup> T cell-mediated antitumor immunity for HER2-positive tumor suppression.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same journal

Hsa_circ_0003258 drives serine biosynthesis and docetaxel resistance in prostate cancer by enhancing IGF2BP3-mediated PSAT1 mRNA stability.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same journal

NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same journal

Autophagy in thyroid cancer: Immune suppression and drug resistance.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
Same journal

Lactate-driven H3K18 lactylation promotes cisplatin resistance in bladder cancer via HNRNPF-Parkin mediated mitophagy.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2026
查看所有相关文章

相关实验视频

Updated: Sep 10, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.1K

针对CLK1/SRSF7轴依赖的替代拼接使胰腺管腺癌对化疗和免疫治疗敏感

Chun Zhang1, Yinhao Chen2, Shuncang Zhu2

  • 1Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China; Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou 350001, China; Department of General Surgery, Mindong Hospital Affiliated to Fujian Medical University, Ningde, Fujian, China.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
|August 21, 2025
PubMed
概括
此摘要是机器生成的。

通过增强DNA修复和免疫抑制,循环RNAcALG8促进胰腺癌的耐药性. 使用反感性寡核酸向这种途径显示出对胰腺管腺癌的治疗潜力.

关键词:
替代拼接耐药性 耐药性 耐药性胰腺管腺癌结合RNA的蛋白质

更多相关视频

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

903
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

相关实验视频

Last Updated: Sep 10, 2025

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells
10:06

Engineering Artificial Factors to Specifically Manipulate Alternative Splicing in Human Cells

Published on: April 26, 2017

9.1K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets
07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

903
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
09:58

Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models

Published on: December 9, 2016

13.9K

科学领域:

  • 分子瘤学
  • 癌症治疗方法
  • 核糖核酸生物学

背景情况:

  • 胰腺管腺癌 (PDAC) 由于获得的耐药性导致的高死亡率.
  • 了解化学抵抗的分子机制对于开发有效治疗至关重要.

研究的目的:

  • 阐明PDAC中耐药性的分子机制.
  • 确定导致药物耐药性的新型促瘤因素.
  • 开发针对性治疗策略来对抗耐药性.

主要方法:

  • 循环RNA测序和液态染色体质谱 (LC-MS) 确定了cALG8和相关的RNA结合蛋白 (RBPs).
  • 用分子生物学技术,单细胞测序,患者衍生器官 (PDO) 和患者衍生异体移植 (PDX) 模型来研究cALG8功能.
  • 针对cALG8的反意义寡核酸 (ASOs) 已在体内开发和评估.

主要成果:

  • 循环RNAcALG8在耐凝胺的PDAC中高度表达,通过替代拼接促进化学抵抗和免疫抑制.
  • cALG8 作为支架,促进 CLK1 介导的 SRSF7 酸化,导致增强的 ATM 表达 (ATM203 变种).
  • 这种机制促进了DNA损伤的修复和免疫微环境的重塑,抵消了gemcitabine的作用.
  • 针对cALG8的ASO与gemcitabine和抗PD-1抗体相结合,显著降低了PDX模型中的瘤负担.

结论:

  • 在PDAC中,cALG8/ CLK1/ SRSF7轴增强了ATM的表达,从而驱动了对gemcitabine的耐药性和免疫抑制瘤微环境.
  • 这项研究提供了针对DNA损伤修复机制的见解,以克服PDAC中的化疗耐药性.
  • 针对cALG8的ASO是一种有前途的胰腺癌治疗策略.